FluoretiQ, which is part of the Deepbridge Life Sciences EIS portfolio, has been selected to participate in Innovate UK's Global Business Innovation Programme (GBIP) focusing on Antimicrobial Resistance.
This year, FluoretiQ will join a delegation representing cutting-edge UK diagnostics, therapeutics, preventatives, and vaccines, headed to Switzerland.
Innovate UK's GBIP supports innovative SMEs in exploring global markets to accelerate business growth. Each GBIP, tailored to specific markets and technology sectors, includes up to 15 ambitious UK businesses looking to expand globally. The program aims to help these businesses explore future opportunities and understand what it takes to succeed on the global stage.
GBIP offers detailed market knowledge, cultural insight, and valuable introductions and connections, opening doors that SMEs might struggle to access independently. Each business is supported by an Innovate UK EDGE innovation and growth specialist to maximize the program's potential and beyond.
FluoretiQ Ltd, born at the Quantum Technology Enterprise Centre (QTEC) in Bristol, envisions revolutionizing bacteria identification. Their innovation—a rapid and straightforward bacteria diagnostic test—utilizes innovative probes and powerful fluorescence sensors to detect and identify bacteria in physiological samples.
- October 2021 (7)
- September 2021 (4)
- August 2021 (4)
- July 2021 (3)
- June 2021 (6)
- May 2021 (5)
- April 2021 (8)
- March 2021 (5)
- February 2021 (5)
- January 2021 (4)
- December 2020 (1)
- November 2020 (4)
- October 2020 (6)
- September 2020 (5)
- August 2020 (5)
- July 2020 (3)
- June 2020 (5)
- May 2020 (6)